HARVARD BIOSCIENCE, INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets
HARVARD BIOSCIENCE, INC. (HBIO) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 5.30% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2024-03-07
- HARVARD BIOSCIENCE, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2023 was 5.30%, a 6.00% increase from fiscal 2022.
- HARVARD BIOSCIENCE, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2022 was 5.00%, a 78.57% increase from fiscal 2021.
- HARVARD BIOSCIENCE, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2021 was 2.80%, a 17.65% decline from fiscal 2020.
- HARVARD BIOSCIENCE, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2020 was 3.40%, a 11.46% decline from fiscal 2019.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month as first filed |
|---|---|---|
| 2023-12-31 | 5.30% 10-K · filed 2024-03-07 | |
| 2022-12-31 | 5.00% 10-K · filed 2024-03-07 | |
| 2021-12-31 | 2.80% 10-K · filed 2023-03-09 | |
| 2020-12-31 | 3.40% 10-K · filed 2022-03-11 | 3.45% 10-K · filed 2021-03-12 |
| 2019-12-31 | 3.84% 10-K/A · filed 2021-03-17 | |
| 2018-12-31 | 4.68% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 3.86% 10-K · filed 2019-03-18 | |
| 2016-12-31 | 4.68% 10-K · filed 2018-03-16 | |
| 2015-12-31 | 4.43% 10-K · filed 2018-03-16 | |
| 2014-12-31 | 4.15% 10-K · filed 2017-03-17 | |
| 2013-12-31 | 3.79% 10-K · filed 2016-04-29 | |
| 2012-12-31 | 4.02% 10-K · filed 2015-03-12 | |
| 2011-12-31 | 4.40% 10-K · filed 2014-03-14 | |
| 2010-12-31 | 5.00% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |